Abstract
Small cell lung cancer (SCLC) is a high-grade neuroendocrine lung carcinoma notable for early dissemination and rapid, albeit transient, responses to standard of care (SOC) treatment [platinum-based chemotherapy plus immune checkpoint blockade (ICB)] that are rapidly undone by refractory relapses. Using single cell profiling, we previously demonstrated that a major factor regulating resistance is an increase in plasticity and transcriptional intratumoral heterogeneity (ITH) in response to treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
